OBJECTIVES: To determine whether highly active antiretroviral therapy (HAART) is associated with reduced HIV-associated neuropsychological impairment. DESIGN: Cross-sectional analysis in a natural history study of adaptation to HIV/AIDS. METHOD: A sample of 130 homo-/bisexual men with HIV/AIDS (mean age, 41 years; 42% non-white) were evaluated with a neuropsychological battery assessing attention, concentration, psychomotor speed, learning, memory and executive function. Subjects taking HAART were compared with those not taking HAART on demographics, CD4 cell count, viral load, scores on individual neuropsychological tests and proportion with neuropsychological impairment. RESULTS: Sixty-nine (53%) subjects were taking HAART, and 48 (37%) were neuropsychologically impaired. Subjects taking HAART had lower mean CD4 cell counts than those not taking HAART (254 versus 342 x 10(6)/l; P < 0.05), although they were more likely to have undetectable viral load (42 versus 20%; P < 0.01) and were less likely to be neuropsychologically impaired (22 versus 54%; P < 0.0001). Subjects taking HAART performed significantly better on tests of attention, concentration, learning, memory, and psychomotor speed. After excluding subjects with potential non-HIV confounders of neuropsychological function, those without neuropsychological impairment had significantly lower mean viral load levels and were more likely to have undetectable viral load than those with impairment. CONCLUSION: These preliminary findings suggest that HAART benefits neuropsychological function through the reduction of viral load.
OBJECTIVES: To determine whether highly active antiretroviral therapy (HAART) is associated with reduced HIV-associated neuropsychological impairment. DESIGN: Cross-sectional analysis in a natural history study of adaptation to HIV/AIDS. METHOD: A sample of 130 homo-/bisexual men with HIV/AIDS (mean age, 41 years; 42% non-white) were evaluated with a neuropsychological battery assessing attention, concentration, psychomotor speed, learning, memory and executive function. Subjects taking HAART were compared with those not taking HAART on demographics, CD4 cell count, viral load, scores on individual neuropsychological tests and proportion with neuropsychological impairment. RESULTS: Sixty-nine (53%) subjects were taking HAART, and 48 (37%) were neuropsychologically impaired. Subjects taking HAART had lower mean CD4 cell counts than those not taking HAART (254 versus 342 x 10(6)/l; P < 0.05), although they were more likely to have undetectable viral load (42 versus 20%; P < 0.01) and were less likely to be neuropsychologically impaired (22 versus 54%; P < 0.0001). Subjects taking HAART performed significantly better on tests of attention, concentration, learning, memory, and psychomotor speed. After excluding subjects with potential non-HIV confounders of neuropsychological function, those without neuropsychological impairment had significantly lower mean viral load levels and were more likely to have undetectable viral load than those with impairment. CONCLUSION: These preliminary findings suggest that HAART benefits neuropsychological function through the reduction of viral load.
Authors: Justin C McArthur; Norman Haughey; Suzanne Gartner; Kathy Conant; Carlos Pardo; Avi Nath; Ned Sacktor Journal: J Neurovirol Date: 2003-04 Impact factor: 2.643
Authors: Monica Rivera Mindt; Mariana Cherner; Thomas D Marcotte; David J Moore; Heather Bentley; Maria M Esquivel; Yanira Lopez; Igor Grant; Robert K Heaton Journal: J Clin Exp Neuropsychol Date: 2003-02 Impact factor: 2.475
Authors: C Zucchella; E Sinforiani; E Tavazzi; S Del Bue; S Novati; R Maserati; M Ceroni; S Bastianello; L Minoli; P Ferrante; E Marchioni Journal: Neurol Sci Date: 2011-06-01 Impact factor: 3.307
Authors: David J Moore; Miguel Arce; Suzanne Moseley; J Allen McCutchan; Jennifer Marquie-Beck; Donald R Franklin; Florin Vaida; Cristian L Achim; Justin McArthur; Susan Morgello; David M Simpson; Benjamin B Gelman; Ann C Collier; Christina M Marra; David B Clifford; Robert K Heaton; Igor Grant Journal: J Neuropsychiatry Clin Neurosci Date: 2011 Impact factor: 2.198
Authors: Kenneth Williams; Susan Westmoreland; Jane Greco; Eva Ratai; Margaret Lentz; Woong-Ki Kim; Robert A Fuller; John P Kim; Patrick Autissier; Prahbat K Sehgal; Raymond F Schinazi; Norbert Bischofberger; Michael Piatak; Jeffrey D Lifson; Eliezer Masliah; R Gilberto González Journal: J Clin Invest Date: 2005-08-18 Impact factor: 14.808
Authors: Miriam E Shapiro; Jeannette R Mahoney; Deena Peyser; Barry S Zingman; Joe Verghese Journal: Arch Clin Neuropsychol Date: 2013-09-09 Impact factor: 2.813